Compare Mesoblast Limited (MESO) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs SoundHound AI Inc — how do they compare? Mesoblast Limited trades at $16.28 (market cap $2.17B), while SoundHound AI Inc trades at $6.45 (market cap $2.75B). The key difference: SoundHound AI Inc is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| MESO | SOUN | |
|---|---|---|
Market Cap | $2.17B | $2.75B |
Sector | Technology | Technology |
52-Week High | $20.96 | $21.40 |
52-Week Low | $12.88 | $5.90 |
Enterprise Value | $2.17B | $2.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SoundHound AI (SOUN) trades at $6.31, down 37% year-to-date amid concerns over persistent losses and cash burn despite 52% revenue growth in 2025. The stock shows a bearish technical trend with neutral oscillators, while fundamentals reveal a negative net income margin of -91.84% and high valuation multiples. Recent positive developments include being named a Leader in Gartner's Magic Quadrant for Conversational AI Platforms (GlobeNewsWire, July 13, 2026) and beating EPS estimates in three consecutive quarters.
The outlook remains speculative with significant upside potential based on a $13.00 analyst consensus price target, but high execution risks and cash burn pose threats. Investment opportunity hinges on the company's ability to monetize its AI platform expansion and achieve profitability, while risks include competitive pressures and reliance on financing to cover operational losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
